Drug profile · INN
risankizumab
SKYRIZI
risankizumab (SKYRIZI) is a interleukin-23 inhibitor. Associated with AbbVie.
Drug details — risankizumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 1
- Programs
- 22
- Data quality
- 0.83
Quick answer
risankizumab (SKYRIZI) is a interleukin-23 inhibitor. Associated with AbbVie.
Key facts
Mechanism of action
Interleukin-23 inhibitor
Primary target: Interleukin-23
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Recent coverage
AbbVie Cerevel acquisition closes in $8.7B neuroscience deal
AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics, paying $45.00 per share in cash. The deal adds neuroscience assets as investors watch emraclidine, pipeline execution, and future filing catalysts.
AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands
AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, after U.S. Federal Trade Commission review. The deal adds Cerevel assets to AbbVie’s neuroscience pipeline and sets up follow-on readouts to watch.
UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape
UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development.
UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis
UCB's Bimzelx has shown superior efficacy compared to AbbVie's Skyrizi in treating psoriatic arthritis, marking a significant milestone in the competitive landscape. This article analyzes the implications for pharmaceutical business development teams.
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is risankizumab?
risankizumab (SKYRIZI) is a interleukin-23 inhibitor. Associated with AbbVie.
What is the brand name for risankizumab?
SKYRIZI is a marketed brand name for risankizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.